Compare Enact Holdings Inc (ACT) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs Novavax Inc — how do they compare? Enact Holdings Inc trades at $49.93 (market cap $6.75B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Enact Holdings Inc is far larger — about 5.2× Novavax Inc's market cap, and Enact Holdings Inc pays a 1.95% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ACT | NVAX | |
|---|---|---|
Market Cap | $6.75B | $1.31B |
Sector | Technology | Health |
52-Week High | $49.12 | $11.19 |
52-Week Low | $34.93 | $6.22 |
Enterprise Value | $7.05B | $889.30M |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
